
    
      This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757
      monotherapy, in combination with anti-PD1 therapy and with additional cytokine release
      syndrome (CRS) mitigation strategies. AMG 757 will be administered as a short term
      intravenous (IV) infusion in subjects with small cell lung cancer. AMG 757 is a Half Life
      Extended (HLE) Bispecific T cell engager (BiTEÂ®) targeting delta-like protein 3 (DLL3)
    
  